S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
NASDAQ:TCON

TRACON Pharmaceuticals Stock Forecast, Price & News

$2.33
+0.06 (+2.64%)
(As of 01/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.20
$2.36
50-Day Range
$2.13
$3.65
52-Week Range
$1.97
$11.76
Volume
79,779 shs
Average Volume
173,830 shs
Market Capitalization
$45.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.77
30 days | 90 days | 365 days | Advanced Chart
Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


TRACON Pharmaceuticals logo

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Headlines

Pre-market Movers: FTK, BVXV, PBTS, SPRB, AHPI…
December 28, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCON
Employees
18
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.83 per share

Profitability

Net Income
$-16.77 million
Pretax Margin
-7,302.31%

Debt

Price-To-Earnings

Miscellaneous

Free Float
18,845,000
Market Cap
$45.31 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/03/2021
Today
1/26/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

443rd out of 1,416 stocks

Biological Products, Except Diagnostic Industry

67th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

Is TRACON Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRACON Pharmaceuticals stock.
View analyst ratings for TRACON Pharmaceuticals
or view top-rated stocks.

How has TRACON Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCON stock has increased by 65.2% and is now trading at $2.33.
View which stocks have been most impacted by COVID-19
.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 307,200 shares, an increase of 38.0% from the December 15th total of 222,600 shares. Based on an average daily volume of 277,400 shares, the days-to-cover ratio is presently 1.1 days.
View TRACON Pharmaceuticals' Short Interest
.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for TRACON Pharmaceuticals
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.06. During the same quarter in the prior year, the firm earned ($0.38) EPS.
View TRACON Pharmaceuticals' earnings history
.

What price target have analysts set for TCON?

5 analysts have issued 12 month target prices for TRACON Pharmaceuticals' shares. Their forecasts range from $13.00 to $24.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 629.6% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the following people:
  • Charles P. Theuer, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Scott B. Brown, Chief Financial Officer
  • Bonne J. Adams, Senior Vice President-Clinical Operations
  • James L. Freddo, Chief Medical Officer
  • Mark C. Wiggins, Chief Business Officer

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cutler Group LP (0.08%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends for TRACON Pharmaceuticals
.

Which major investors are buying TRACON Pharmaceuticals stock?

TCON stock was acquired by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier, and Scott B Brown.
View insider buying and selling activity for TRACON Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $2.33.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals has a market capitalization of $45.31 million. The biopharmaceutical company earns $-16.77 million in net income (profit) each year or ($1.60) on an earnings per share basis.

How many employees does TRACON Pharmaceuticals have?

TRACON Pharmaceuticals employs 18 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

Where are TRACON Pharmaceuticals' headquarters?

TRACON Pharmaceuticals is headquartered at 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at [email protected], or via fax at 858-550-0786.


This page was last updated on 1/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.